PDCD1 and myocarditis: Compared with anti-CTLA-4 or anti-PD-L1, anti-PD-1 showed a stronger signal value in myocarditis, especially nivolumab (IC025 = 4.10), which corresponded with the findings of Ji et al. (2019).